



# **Patently Obvious – The 2002 Danish EU Presidency Warned of COVID Crimes**

**Dr. David E. Martin**

**Chairman, M • CAM International**

**Batten Fellow, University of Virginia**

# It was always a Criminal Conspiracy of Bioterrorism



To **sustain the funding base** beyond the crisis we need to increase public understanding of the need for MCMs (medical countermeasures) such as a pan-influenza or **pan-coronavirus vaccine**. **A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process'.**

- Peter Daszak, National Academy of Science March 2015

[Developing MCMs for Coronaviruses - Rapid Medical Countermeasure Response to Infectious Diseases - NCBI Bookshelf \(nih.gov\)](#)

# **Danish Presidency Conference 2002: Growth, Prosperity and Patents**

- **Denmark had adopted DIRECTIVE 98/44/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL**
  - **Chapter 1, Article 5 allowed for the patentability of genetic material isolated from humans**
  - **Europe was dealing with the Myriad Genetics patents on Breast Cancer genes – and wasn't thinking about CoV**
- **During my presentation in Aalborg...**
  - **Discussed the EPO's disregard for software patent law**
  - **Discussed the EPO's disregard for biologics patent law**
  - **Was joined by DKPTO's Director General Mogens Kring in calling for oversight**

# ...with CoV bioweapons already in production

## STATEMENT OF FEDERAL SUPPORT

This invention was made possible with government support under grant numbers [AI23946](#) and [GM63228](#) from the National Institutes of Health. The United States government has certain rights to this invention.



*Proc. Natl. Acad. Sci. U.S.A.*, 2003 Oct 28; 100(22): 12995-13000. PMID: PMC240733  
Published online 2003 Oct 20. doi: 10.1073/pnas.1735582100 PMID: 14569023

Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus

Boyd Yount,<sup>1</sup> Kristopher M. Curtis,<sup>1\*</sup> Elizabeth A. Fritz,<sup>1</sup> Lisa E. Hensley,<sup>2</sup> Peter B. Jahrling,<sup>2</sup> Erik Prestice,<sup>3</sup> Mark R. Denison,<sup>3</sup> Thomas W. Geisbert,<sup>2</sup> and Ralph S. Baric<sup>1</sup>

\* Author information • Article notes • Copyright and License information • Disclaimer

This work was supported by National Institutes of Health Grants [AI23946](#), [GM63228](#) (to R.S.B.), and AI26603 (to M.R.D.). The research was supported by the Carolina Vaccine Institute at the University of North Carolina, Chapel Hill.



US007279327B2

**(12) United States Patent**  
Curtis et al.

**(10) Patent No.:** US 7,279,327 B2  
**(45) Date of Patent:** Oct. 9, 2007

**(54) METHODS FOR PRODUCING RECOMBINANT CORONAVIRUS**

**(75) Inventors:** Kristopher M. Curtis, Chapel Hill, NC (US); Boyd Yount, Hillsborough, NC (US); Ralph S. Baric, Haw River, NC (US)

**(73) Assignee:** The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)

**(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 33 days.

**(21) Appl. No.:** 10/474,962

**(22) PCT Filed:** Apr. 19, 2002

**(86) PCT No.:** PCT/US02/12453  
§ 371 (c)(1), (2), (4) Date: May 25, 2004

**(87) PCT Pub. No.:** WO02/086068  
PCT Pub. Date: Oct. 31, 2002

**(65) Prior Publication Data**  
US 2004/0235132 A1 Nov. 25, 2004

**Related U.S. Application Data**

**(60)** Provisional application No. 60/285,320, filed on Apr. 20, 2001, provisional application No. 60/285,318, filed on Apr. 20, 2001.

**(51) Int. Cl. C12N 15/85 (2006)**  
**C12N 15/63 (2006)**

**(52) U.S. Cl. 437**

**(58) Field of Classification:** See application file for OTHER P

**(56) References:**  
Goedeke et al. *J. Virol.* 2000, vol. 74, No. 4, pp. 1833-1840.  
Izeta et al. *J. Virol.* Feb. 1999, vol. 73, No. 4, pp. 1833-1840.  
Fisher et al. *J. Virol.* 1997, vol. 71, No. 7, pp. 5148-5160.

**(57) ABSTRACT**

**(3) While the present invention is directed to an infectious, replication defective, porcine transmissible gastroenteritis virus (TGEV), the invention may be carried out with any coronavirus, such as human respiratory coronavirus, porcine coronavirus, feline infectious peritonitis virus, rabbit coronavirus, and the like.**

US007220852B1

**(12) United States Patent**  
Rota et al.

**(10) Patent No.:** US 7,220,852 B1  
**(45) Date of Patent:** May 22, 2007

**(54) CORONAVIRUS ISOLATED FROM HUMANS**

**(75) Inventors:** Paul A. Rota, Decatur, GA (US); Larry J. Anderson, Atlanta, GA (US); William J. Bellini, Lilburn, GA (US); Cara Carthel Burns, Avondale Estates, GA (US); Raymond Campagnoli, Decatur, GA (US); Qi Chen, Marietta, GA (US); James A. Comer, Decatur, GA (US); Shannon L. Emery, Lusaka (ZM); Dean D. Erdman, Decatur, GA (US); Cynthia S. Goldsmith, Lilburn, GA (US); Charles D. Humphrey, Lilburn, GA (US); Joseph P. Icenogle, Atlanta, GA (US); Thomas G. Ksiazek, Lilburn, GA (US); Stephan S. Monroe, Decatur, GA (US); William Allan Nix, Bethlehem, GA (US); M. Steven Oberste, Lilburn, GA (US); Teresa C. T. Peret, Atlanta, GA (US); Pierre C. Rollin, Lilburn, GA (US); Patrick F. T. Faloutsos, Lilburn, GA (US); Li Xiang Tong, Alpharetta, GA (US); Sherif R. Zaki, Atlanta, GA (US)

**(73) Assignee:** The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Washington, DC (US)

**(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

**(21) Appl. No.:** 10/822,904

**(22) Filed:** Apr. 12, 2004

**Related U.S. Application Data**

**(60)** Provisional application No. 60/465,927, filed on Apr. 25, 2003.

**FOREIGN PATENT DOCUMENTS**

WO WO 2004/085633 \* 10/2004  
WO WO 2004/092360 \* 10/2004

**OTHER PUBLICATIONS**

GenBank Accession No. AY274119, "SARS Coronavirus Tor2, complete genome," version AY274119.1, Apr. 14, 2003.\*  
GenBank Accession No. AY278487, "SARS coronavirus B302, partial genome," version AY278487.1, Apr. 21, 2003.\*  
GenBank Accession No. AY278554, "SARS coronavirus CUHK-W1, complete genome," version AY278554.1, Apr. 18, 2003.\*  
GenBank Accession No. AY278491, "SARS Coronavirus HKU-39849, complete genome," version AY278491.1, Apr. 18, 2003.\*  
SARS-associated Coronavirus. Genomic Sequence Availability. [online] [retrieved on Aug. 8, 2005]. Retrieved from the Internet <URL: http://www.bcgsc.ca/bioinfo/SARs>.\*  
GenBank Accession No. AY274119, Apr. 14, 2003.  
GenBank Accession No. AY278741, Apr. 21, 2003.  
"Update: Outbreak of Severe Acute Respiratory Syndrome—Worldwide, 2003," *MMWR Weekly* 32:241-248 (2003).  
Sanchez, Lilburn, GA (US); Li Xiang Tong, Alpharetta, GA (US); Sherif R. Zaki, Atlanta, GA (US).  
Goldsmith et al., "Ultrastructural Characterization of SARS Coronavirus," *Emerg. Infect. Diseases* 10:320-326 (2004).  
Ksiazek et al., "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," *N. Eng. J. Med.* 348:1953-1966 (2003).  
Luo and Luo, "Initial SARS Coronavirus Genomic Sequence Analysis Using a Bioinformatics Platform," 2<sup>nd</sup> Asia-Pacific Bioinformatics Conference (APBC 2004), Dunedin, New Zealand (2004).  
Marra et al., "The Genome Sequence of the SARS-Associated Coronavirus," *Science* 300:1393-1404 (2003).  
Supplementary Online Material for Marra et al. <www.sciencemag.org/cgi/content/full/1085953/DC1>.\*  
Rota et al., "Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome," *Science* 300:1394-1399 (2003).  
Supplementary Online Material for Rota et al. <www.sciencemag.org/cgi/content/full/1085952/DC1>.\*

\* cited by examiner


**Primary Examiner—**Mary E. Mosher  
**(74) Attorney, Agent, or Firm—**Klarquist Sparkman LLP

April 20, 2001


April 25, 2003

III. While the present invention is directed to an infectious, replication defective, porcine transmissible gastroenteritis virus (TGEV), the invention may be carried out with any coronavirus, such as human respiratory coronavirus, porcine coronavirus, feline infectious peritonitis virus, rabbit coronavirus, and the like.

# ...and the evening and the morning and the NEXT DAY – a SARS Vaccine!



**How could they know?  
2 HIV/AIDS and Malaria  
Researchers?**



**Sequoia Pharmaceuticals Raises \$35 Million In Series C Financing**

Published: Jan 09, 2007

GAITHERSBURG, Md., Jan. 8 /PRNewswire/ -- Sequoia Pharmaceuticals, Inc. announced today that it has raised \$35 million in a Series C financing that will be used to further develop its pipeline candidates for the treatment of drug-resistant HIV infections, including the company's two lead clinical candidates, an HIV protease inhibitor as well as a novel therapeutic agent: a Pharmacokinetic Enhancer. The Wellcome Trust led the round of financing and was joined by other existing investors including Healthcare Venture, Sofinova Partners, and Aberdare Ventures as well as new investor, MedImmune Ventures, Inc. As a result, Julie Eskay-Eagle of Wellcome Trust and Wayne T. Hockmeyer, Ph.D., President of MedImmune Ventures and Chairman of the Board, former CEO and founder of MedImmune, Inc., join the Sequoia board.

Scientists at the Centers for Disease Control and Prevention (CDC) and other laboratories around the world have detected a previously unrecognized coronavirus in patients with SARS. The evidence for a coronavirus was based on genetic fingerprint and electron microscopic ultrastructural studies and was widely reported in the popular press. Laboratories all reported that a coronavirus is the leading hypothesis for the cause of SARS.

The CDC recently reported sequencing the genome for SARS-CoV (Urbani strain), a strain of a novel human coronavirus believed to be responsible for SARS. The sequence data confirm that the SARS virus is a previously unrecognized coronavirus. The virus was cultured from cells taken from a throat culture taken from a SARS patient and grown in Vero cells (African green monkey kidney cells) in order to reproduce the ribonucleic acid (RNA) of the disease-causing coronavirus. The new sequence has 29,727 nucleotides, which places it well within the typical RNA boundaries for coronaviruses. Members of this viral family tend to have between 29,000 and 31,000 nucleotides. See Lai et al., *Adv. Virus Res.* 48:1, (1997). The genome organization of the SARS virus also is similar to that of other coronaviruses.

The genome sequence of SARS-CoV (Urbani) is available from GenBank at the Web site for the National Center for Biotechnology Information, National Library of Medicine <http://www.ncbi.nlm.nih.gov/>. The accession number for the sequence of SARS-CoV (Urbani strain) is ay278741.



# It Started So Simply...58 years ago!

## Coronavirus described in 1965

Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. *Lancet*. 1966;1:76-77.

## Respiratory Tract CoV harvested in 1966

McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. *Proc Natl Acad Sci USA*. 1967;57:933-940.

## USA CoV Sent to Britain to infect subjects

Bradburne AF, Bynoe ML, Tyrrell DA. Effects of a "new" human respiratory virus in volunteers. *Br Med J*. 1967;3:767-769.

## CoV In Humans Basically the "Common Cold"

McIntosh K, Ellis EF, Hoffman LS, Lybass TG, Eller JJ, Fulginiti VA. Association of viral and bacterial respiratory infection with exacerbations of wheezing in young asthmatic children. *Chest*. 1973;63(suppl):43S.

## Chimeric CoV Known to Target Heart Tissue (Cardiomyopathy)

Alexander LK, Small JD, Edwards S, Baric RS. An experimental model for dilated cardiomyopathy after rabbit coronavirus infection. *J Infect Dis*. 1992 Nov;166(5):978-85.

## Pfizer Patents CoV S-protein Vaccine

U.S. Patent 6,372,224 November 2000

## The mRNA Vaccine "model" is patented as "an infectious, replication defective clone"

Kristopher M. Curtis, Boyd Yount, Ralph S. Baric, U.S. Patent 7,279,327 April 2002

# SARS

2002-2003

## CDC Files Patent on "Coronavirus Isolated From Humans" and takes control of CoV GoF

U.S. Patent 7,220,852 April 2003



# So Many Warning Signs... so little attention

## RT-PCR SARS CoV Modifications Briefed as Bioterrorism Threat

Martin, DE, M•CAM 2003 – Bioweapons and Vector Weaponization.

Between 2002 and 2010, the EU Parliament convened frequent hearings on the patenting of nature and bioengineering and dangers arising therefrom

## DARPA and NIAID Co-invest in UNC / Wuhan / EcoHealth Alliance

Baric, Zhengli Shi, Daszak 2005 with USAID PREDICT

## SARS-like WIV1-CoV poised for human emergence

"we next evaluated in vivo infection following WIV1-MA15 and WIV1-CoV challenge"

*Proceedings of the National Academy of Sciences of the United States of America* (2016) 113(11) 3048-3053

## Prospect of CoV as Bioweapon Linked to Anthrax

Keystone Symposium Bioterrorism and Emerging Infectious Diseases: Antimicrobials, Therapeutics and Immune-Modulators

Ralph S. Baric, University of North Carolina at Chapel Hill, USA  
*Reverse Genetics with a Full-Length Infectious cDNA of the Severe Acute Respiratory Disease Syndrome Coronavirus*. January 2004

Martin DE. 2004. "Proliferation and commercialization of biological and chemical agents for military and civilian use" European Section, 15th European Symposium on Animal, Plant and Microbial Toxins (Eurotox). Ljubljana, Slovenia.

Biodefense Grant U54 AI057157 commences with \$10,189,682 to UNC Chapel Hill

## US GAIN OF FUNCTION MORATORIUM 2014 ...with UNC Chapel Hill exception

## "The Accidental or Intentional Release of A Respiratory Pathogen"

European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe. European Commission. 17 December 2019.

## The mRNA Spike Protein WEAPON is Designed

Synthetic Coronaviruses. Biohacking: **Biological Warfare Enabling Technologies**, June 2005. Washington, DC. DARPA/MITRE sponsored event

Martin DE. 2005. "Proliferation of Bioengineering Technologies." Keynote Address for National Research Center for Genetic Engineering and Biotechnology International Congress on Bioethics 2005. Tehran, Islamic Republic of Iran.

## Moderna and BioNTech begin mRNA Vaccine Development 2010 - 2018

# Would We Recognize Anti-Trust if it Was In Our Face?



Eliza Mannigham-Buller (launch of COVID)



Julia Gillard (current)



← Jeremy Farrar →





MEMBERS OF THE GLOBAL PREPAREDNESS MONITORING BOARD

	H.E. Dr Gro Harlem Brundtland Co-Chair, GPMB, former Prime Minister, Norway and former Director-General, World Health Organization		Mr Elhadj As Sy Co-Chair, GPMB, Secretary-General, World Bank and former Director-General, World Health Organization
	Dr Victor Dzau President, The National Academy of Medicine, USA		Dr Chris Eliss President, Global Development Program, Bill & Melinda Gates Foundation, USA
	Sir Jeremy Farrar Director, Wellcome Trust, UK		Dr Anthony S. Fauci Director, National Institute of Allergy and Infectious Diseases, USA
	Ma Henrietta Fore Executive Director, UNICEF		Dr George Gao Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China




Dame Amelia Fawcett





# The Pharmaceutical Conquest of Science... ...by 3 industrialists



aspirin, chloroform (from alcohol), cholesterol, cocaine, emetine bismuthous iodide (amoebic dysentery), flavine, hydroquinone, lanoline and phenacetin



- 1910 – Carnegie funded Flexner Report
- 1916 – Rockefeller funds and founds Johns Hopkins University of Public Health and vaccine program
- 1920's – injectable insulin
- 1930's – digoxin
- 1941 – Therapeutic Research Corporation in response to the Therapeutic Substances Act (and Wellcome heads the National Institute for Medical Research)
- 1947 – **WHO** founded by Dr. René Sand (Dachau prisoner of the Nazis funded by the Rockefeller Foundation)
- 1950 – WHO TB vaccine campaign launched (funded in part by the Rockefeller Foundation)
- 1952 – WHO D.G. Brock Chisholm advocates for “population control” as a **WHO priority**
- 1955 – WHO Malaria vaccine program started
- 1955 – Burroughs Wellcome Fund established in the U.S.
- 1967 – WHO Smallpox eradication program launched
- 1974 – Essential Program on Immunization launched
- 1988 – WHO launches Polio eradication program
- 2006 – WHO launches HPV campaign
- 2011 – Decade of Vaccines solidifies GF and GAVI as global lead
- 2023 – Gates Foundation provides 88% of WHO donations (along with Bloomberg, Wellcome, and Rockefeller)

# Anatomy of the Crime

**Foundations Illegally Fund  
“Research Institutions” and “NGOs”  
disguising **MARKETING** as  
Philanthropy**

**“Investors respond  
if they see **PROFIT**  
and the end of the  
**PROCESS**”**



**“Science-based”  
policy is mandated  
through coercion of  
corporations who  
receive Federal Funds**

- **Patent on the “Pathogen”  
(restraint of trade & bioweapons)**
- **Sole-source, non-competitive  
“academic” grants (market  
allocation)**
- **“Science”, Industry, and NGOs  
sit on commercial boards  
(interlocking directorates)**
- **Collusion leads to “Emergency”  
wargames to modify (coerce)  
behavior (conspiring to criminal  
commercial activity)**
- **Suppression of known market  
options (market allocation and  
Deceptive Medical Practices)**
- **Selection of known lethal agents  
(murder)**

# Keep It Simple – Anti-Trust Laws are Key

## For Commercial Gain and Population Control:

- **Criminal Racketeers conspired to use an “emergency”**
- **Criminal Racketeers suppressed market opportunities in planning (patenting), manufacturing (non-competitive grants & contracts), and agency capture (deceptive medical practices)**
- **Criminal Racketeers violated ‘interlocking directorates’ independence rules leading to public price fixing and market manipulation**
- **Criminal Racketeers enlisted conflicted “experts” to promulgate propaganda (terrorism and coercion)**
- **Criminal Racketeers publicly lied under oath to deny their complicity...**

**...which resulted in the death and disability of millions**

